Your browser doesn't support javascript.
loading
Dual Relief of T-lymphocyte Proliferation and Effector Function Underlies Response to PD-1 Blockade in Epithelial Malignancies.
Balança, Camille-Charlotte; Scarlata, Clara-Maria; Michelas, Marie; Devaud, Christel; Sarradin, Victor; Franchet, Camille; Martinez Gomez, Carlos; Gomez-Roca, Carlos; Tosolini, Marie; Heaugwane, Diana; Lauzéral-Vizcaino, Françoise; Mir-Mesnier, Lucile; Féliu, Virginie; Valle, Carine; Pont, Frédéric; Ferron, Gwénaël; Gladieff, Laurence; Motton, Stéphanie; Tanguy Le Gac, Yann; Dupret-Bories, Agnès; Sarini, Jérôme; Vairel, Benjamin; Illac, Claire; Siegfried-Vergnon, Aurore; Mery, Eliane; Fournié, Jean-Jacques; Vergez, Sébastien; Delord, Jean-Pierre; Rochaix, Philippe; Martinez, Alejandra; Ayyoub, Maha.
  • Balança CC; Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France.
  • Scarlata CM; Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France.
  • Michelas M; Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France.
  • Devaud C; Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France.
  • Sarradin V; Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France.
  • Franchet C; Department of Medical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France.
  • Martinez Gomez C; Department of Pathology, Centre Hospitalier Universitaire, Institut Universitaire du Cancer de Toulouse, Toulouse, France.
  • Gomez-Roca C; Université Toulouse III Paul Sabatier, Toulouse, France.
  • Tosolini M; Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France.
  • Heaugwane D; Department of Surgery, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France.
  • Lauzéral-Vizcaino F; Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France.
  • Mir-Mesnier L; Department of Medical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France.
  • Féliu V; Technological Pole and Bioinformatic Platform, Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France.
  • Valle C; Department of Pathology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France.
  • Pont F; Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France.
  • Ferron G; Université Toulouse III Paul Sabatier, Toulouse, France.
  • Gladieff L; Immune Monitoring Core Facility, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France.
  • Motton S; Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France.
  • Tanguy Le Gac Y; Technological Pole and Bioinformatic Platform, Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France.
  • Dupret-Bories A; Technological Pole and Bioinformatic Platform, Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France.
  • Sarini J; Department of Surgery, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France.
  • Vairel B; Department of Medical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France.
  • Illac C; Department of Surgery, Centre Hospitalier Universitaire, Institut Universitaire du Cancer de Toulouse, Toulouse, France.
  • Siegfried-Vergnon A; Department of Surgery, Centre Hospitalier Universitaire, Institut Universitaire du Cancer de Toulouse, Toulouse, France.
  • Mery E; Department of Surgery, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France.
  • Fournié JJ; Department of Surgery, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France.
  • Vergez S; Department of Surgery, Centre Hospitalier Universitaire, Institut Universitaire du Cancer de Toulouse, Toulouse, France.
  • Delord JP; Department of Pathology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France.
  • Rochaix P; Department of Pathology, Centre Hospitalier Universitaire, Institut Universitaire du Cancer de Toulouse, Toulouse, France.
  • Martinez A; Department of Pathology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France.
  • Ayyoub M; Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France.
Cancer Immunol Res ; 8(7): 869-882, 2020 07.
Article en En | MEDLINE | ID: mdl-32295784
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Antígenos CD28 / Neoplasias Glandulares y Epiteliales / Linfocitos T CD8-positivos / Receptor de Muerte Celular Programada 1 / Antineoplásicos Inmunológicos Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Antígenos CD28 / Neoplasias Glandulares y Epiteliales / Linfocitos T CD8-positivos / Receptor de Muerte Celular Programada 1 / Antineoplásicos Inmunológicos Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Año: 2020 Tipo del documento: Article